Home/ Supplements/ Omega 3/ OMGA LQ

OMGA LQ

product on market Liquid Systemic Formulas Bio Nutriment Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 30% of ingredients have research evidence
A Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

This product provides omega-3 fatty acids, including DHA, EPA, and alpha-linolenic acid. Strong evidence suggests these components support cardiovascular health and cognitive function. However, the overall evidence coverage for this specific formulation is very limited.

AI-generated summary based on research evidence. Not medical advice.

Label

Product Label

Label for OMGA LQ
Open Full PDF View on NIH DSLD →
Details

Label Data

2 mL
Serving Size
30
Servings
Fat/Fatty Acid
Product Type
30%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

Calories
18 {Calories}
Total Fat
1.8 g (3% DV)
Market median: 750.0mg (447 products) 393 studies (A:18, B:204)
Market median: 750.0mg (447 products) 393 studies (A:18, B:204)
Alpha-Linolenic Acid
125 mg
Market median: 750.0mg (447 products) 393 studies (A:18, B:204)
Gamma-Linolenic Acid
12 mg
Linoleic Acid
40.6 mg
Oleic Acid
10.8 mg
Other Fatty Acids

Other Ingredients

Tropical Oils Natural Flavors Tocopherol Rosemary extract CoQ10
Claims

Label Claims — Verification

Unverified All Other
Unverified Structure/Function
Info

Product Information

Directions for Use

DIRECTIONS: TAKE 2 mL DAILY.

Formulation Notes

No sugar. No alcohol. No artificial color. No artificial flavor.

Omega Fatty Acids DHA, EPA (3,3,9)

Additional Information

#197 I/8

SUPER CONCENTRATE

Ultra pure OMGA LQ essential fatty acids (Omega 3,6,9) promotes healthy heart, brain, and joints.

KEEP REFRIGERATED

MADE IN U.S.A.

Metadata

Product Details

UPC / SKU6 35585 01971 2
DSLD Entry Date2013-06-25
Product TypeFat/Fatty Acid
FormLiquid
DSLD ID22120
Data Updated2026-04-11
Research

Research Evidence

495
Research Sources
56
Avg Quality
222
Meta Analysis
104
Clinical Trial
72
Rct
69
Systematic Review
11
Guideline
5
Cochrane Review
5
Regulatory Source
3
Narrative Review
1
Openfda Safety
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
A Omega-3 fatty acid addition during pregnancy
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Omega-3 fatty acids for depression in adults
Systematic Review The Cochrane database of systematic reviews 2021 PubMed DOI
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Non-immunosuppressive treatment for IgA nephropathy
Meta Analysis The Cochrane database of systematic reviews 2024 PubMed DOI
A Omega-3 fatty acid supplementation for depression in children and adolescents
Meta Analysis The Cochrane database of systematic reviews 2024 PubMed DOI
A Interventions for fatigue and weight loss in adults with advanced progressive illness
Meta Analysis The Cochrane database of systematic reviews 2012 PubMed DOI
A Motor control exercise for chronic non-specific low-back pain
Meta Analysis The Cochrane database of systematic reviews 2016 PubMed DOI
A Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
View all evidence for Omega 3 →
Compare

Similar Products

View all Omega 3 products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.